Perspectives on the clinical development of immunotherapy in prostate cancer.
- Author:
Lisa M CORDES
1
;
James L GULLEY
2
;
Ravi A MADAN
2
Author Information
- Publication Type:Review
- Keywords: checkpoint inhibitor; immunotherapy; prostate cancer; therapeutic vaccine
- MeSH: Animals; Antineoplastic Agents, Immunological/therapeutic use*; Antineoplastic Combined Chemotherapy Protocols/therapeutic use*; B7-H1 Antigen/antagonists & inhibitors*; Benzamides; CTLA-4 Antigen/antagonists & inhibitors*; Cancer Vaccines/therapeutic use*; Humans; Immunotherapy; Ipilimumab/therapeutic use*; Male; Nitriles; Phenylthiohydantoin/analogs & derivatives*; Programmed Cell Death 1 Receptor/antagonists & inhibitors*; Prostatic Neoplasms/drug therapy*; Tissue Extracts/administration & dosage*
- From: Asian Journal of Andrology 2018;20(3):253-259
- CountryChina
- Language:English
- Abstract: Despite impressive survival benefits with immunotherapy in patients with various solid tumors, the full potential of these agents in prostate cancer has yet to be realized. Sipuleucel-T demonstrated a survival benefit in this population, indicating that prostate cancer is an immunoresponsive disease; however, these results have not been matched by other agents. A large trial with ipilimumab in prostate cancer failed to meet its primary objective, and small trials with PD-1/PD-L1 inhibitors did not yield a significant improvement in overall response. However, several late-stage clinical trials are underway with other vaccines in prostate cancer. Reports of clinical benefit with immunotherapies, particularly when used in combination or a select population, have provided the framework to develop sound clinical trials. Understanding immunogenic modulation, antigen spread, biomarkers, and DNA-repair defects will also help mold future strategies. Through rational patient selection and evidence-based combination approaches, patients with prostate cancer may soon derive durable survival benefits with immunotherapies.
